Designation of orphan drugs to be redefined

The government will redefine the designation rule of orphan drugs as part of its efforts to reflect the current market situation, according to the Korea Food and Drug Administration.

Under the current regulation, a medicine can be designated as an orphan drug, when the number of Korean patients suffering rare disease is less than 20,000 and the annual import or production volume is valued at...